This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Myocardial Oedema in Acute Myocardial Infarction (AMI)

This study has been completed.
Information provided by (Responsible Party):
Barts & The London NHS Trust Identifier:
First received: September 29, 2009
Last updated: January 31, 2013
Last verified: September 2009

Despite recent improvements in treatment, myocardial infarction (heart attack) is still a leading cause of illness and death in the UK. Following the acute event, it is difficult to predict which patients are at risk of further problems, such as heart failure and is therefore difficult to know which patients need more aggressive/intensive treatment and monitoring.

There needs to be a test which is safe, reliable and reproducible that can be used shortly after a heart attack to both predict future cardiac events and to allow the efficacy of new treatments to be assessed.

Myocardial oedema (swelling of the heart muscle) has been demonstrated using Cardiac Magnetic Resonance (CMR), to occur following a heart attack and has been suggested as a marker for future cardiac events. The optimum time to perform this scan, the method of data analysis and it's effectiveness as a predictor of future cardiac events has not been adequately assessed.

This trial will assess the amount and natural time-course of oedema in the first 10 days following a heart attack. It will also correlate the amount of oedema with the size of scar (damaged heart muscle) and left ventricular ejection fraction (heart function) at 3 months to assess if it is a predictive marker.

Myocardial Infarction

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Determination of the Time Course of Myocardial Oedema Post Myocardial Infarction Treated With Primary Angioplasty Using Cardiac Magnetic Resonance Imaging

Resource links provided by NLM:

Further study details as provided by Barts & The London NHS Trust:

Primary Outcome Measures:
  • Extent and time course of myocardial oedema over the first 10 days post MI [ Time Frame: Days 1, 3 and 10 post MI ]

Secondary Outcome Measures:
  • Left ventricular ejection fraction and left ventricular scar size at 3 months [ Time Frame: 90 days post MI ]

Enrollment: 20
Study Start Date: November 2009
Study Completion Date: October 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Post MI patients
Patients recruited following a successfully reperfused myocardial infarction using primary angioplasty.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients admitted to The London Chest Hospital following an ST elevation myocardial infarction who have been successfully treated with primary angioplasty.

Inclusion Criteria:

  1. Patients presenting to the London Chest Hospital with acute ST elevation myocardial infarction and treated with primary angioplasty and stent implantation within 12 hours of symptom onset
  2. Acute PCI / stent implantation has been successful (residual stenosis visually < 30% and TIMI flow ≥ 2)
  3. At the time of inclusion, the patient no longer requires intravenous catecholamines or mechanical hemodynamic support (aortic balloon pump)
  4. Serum troponin >1ng/ml 12 hours after onset of pain
  5. The patient is able to give written informed consent
  6. The patient must be able to understand and communicate in English

Exclusion Criteria:

  1. Known cardiomyopathy
  2. Previous documented myocardial infarction
  3. Previous percutaneous coronary intervention or coronary artery bypass surgery
  4. Significant renal dysfunction (EGFR<30)
  5. Systemic steroid therapy
  6. Current non steroidal anti-inflammatory drug use
  7. Chronic inflammatory disease
  8. Neoplastic disease without documented remission within the past 5 years
  9. Pregnancy
  10. Reduced mental capacity leading to inability to obtain informed consent
  11. Participation in another clinical trial within the last 30 days
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00987259

United Kingdom
The London Chest Hospital
London, Greater London, United Kingdom, E2 9JX
Sponsors and Collaborators
Barts & The London NHS Trust
Principal Investigator: Thomas R Burchell, BSc, MB BS Bart's and The London NHS Trust, United Kingdom
  More Information


Responsible Party: Barts & The London NHS Trust Identifier: NCT00987259     History of Changes
Other Study ID Numbers: BLT006964
Study First Received: September 29, 2009
Last Updated: January 31, 2013

Keywords provided by Barts & The London NHS Trust:
Myocardial infarction
Myocardial oedema
Magnetic resonance

Additional relevant MeSH terms:
Myocardial Infarction
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases processed this record on September 21, 2017